Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?

There has been an intensive effort to develop novel therapies for the treatment of metastatic colorectal cancer (mCRC). The anti-epidermal growth factor receptor (EGFR) antibodies panitumumab and cetuximab and the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab have demonstrated...

Descripción completa

Detalles Bibliográficos
Autor principal: Marshall, John L.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792961/
https://www.ncbi.nlm.nih.gov/pubmed/20016807
http://dx.doi.org/10.1155/2009/937305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792961/
https://www.ncbi.nlm.nih.gov/pubmed/20016807
http://dx.doi.org/10.1155/2009/937305

Ejemplares similares